Costco Tops Fiscal 1Q18 Estimates

Costco Wholesale (COST) reported stronger-than-expected fiscal 1Q18 results, surpassing analysts’ expectations for both sales and EPS (earnings per share).

Pre-Market Report: Global Markets Are Weak on December 15

After a pullback on Thursday, the Shanghai Composite Index opened lower on December 15 and fell to five-week low price levels.

US Markets Had a Mixed Performance on December 14

The S&P 500 started this week on a stronger note. Despite a strong start, the market lost momentum as the week progressed and fell on Thursday.

Can Kohl’s Stock Pick Up Some Momentum?

Kohl’s (KSS) stock price has risen 1.8% on a YTD (year-to-date) basis as of December 12.


GlaxoSmithKline (GSK) Closing Price
Analyzing Expectations for GlaxoSmithKline's 3Q15 Earnings

GlaxoSmithKline (GSK) is set to release its earnings on October 28, 2015. Analysts estimate an EPS of 0.39 pounds for 3Q15.

How Did IHF Perform on October 14, 2015?

As of October 14, 2015, the iShares U.S. Healthcare Providers ETF (IHF) gave a return of -1%, while the SPDR S&P 500 ETF (SPY) gave a return of -0.5%.

US Equity Market Update for October 13, 2015

Johnson & Johnson (JNJ) has a market cap of $264.3 billion. Its YTD price movement was stable. It was in a trading range until the earnings report in 3Q15.

Eli Lilly's Termination of Evacetrapib and the Aftermath

On October 12, 2015, Eli Lilly and Company announced its decision to terminate the cardiovascular drug Evacetrapib during its phase 3 trial.

How Did IBB's Subgroups Perform on October 13, 2015?

Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.

What Impacted the iShares US Medical Devices ETF on October 12?

On October 12, the iShares US Medical Devices ETF rose by 0.15% to close at $115.35. The broader market SPDR S&P 500 ETF (SPY) rose by 0.09%.

Volatility in Biotech Sector Pushes IBB below SPY Last Week

Dyax gained 21.3% for the week ended October 9. It has been on an upward trend since it received positive results for EU orphan medical product designation for DX-2930.

Alkermes's Aristada in the Wake of FDA Approval

Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.

XBI Underperforms Compared to Broader Market on October 8

The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.

Analyzing Biotech ETFs' Different Subgroups for October 7, 2015

The tug-of-war between the bulls and bears continues in the biotech sector. The biotech stocks rose again and regained some of their lost ground on October 6.

The FDA Approved Merck's Keytruda for Lung Cancer Treatment

On October 2, 2015, the U.S. Food and Drug Administration approved Merck’s Keytruda to treat patients suffering with advanced non-small cell lung cancer.

Biotech Stocks Fall Again Due to a Sell-Off Wave

Illumina (ILMN) fell by 10.6% on Tuesday, October 6. It announced an estimated third-quarter revenue of ~$550 million. Illumina closed at $145.81.

How Did XLV's Subgroups Perform on October 5?

The Health Care Select Sector SPDR ETF (XLV) offers a range of investment opportunities in different sectors of the biotech industry.

How Did the iShares Nasdaq Biotechnology ETF Perform Last Week?

The iShares Nasdaq Biotechnology ETF (IBB) gained 1.71% for the week while the broader market SPDR S&P 500 ETF (SPY) gained 1.1% for the same period.

Health Care Select Sector SPDR ETF: A Comeback with Small Gains

XLV outperformed the broader market representative SPDR S&P 50 ETF on October 1, 2015. SPY rose by 0.26% , compared with XLV’s 1.01%.

Perrigo: A Must-Read Company Overview

Perrigo is a leading healthcare supplier. It develops and distributes over-the-counter prescription pharmaceutical and nutritional products.

Novo Nordisk: A Biotech Giant in Insulin Therapy

Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world.

Last Week's Biotech Tailspin Sends Stocks Plummeting

Last week was an unforgettable week for biotech stocks. It began on a bad note after Hillary Clinton commented on price controls for the specialty drug market, which created panic and triggered a sell-off.

Graph Part 1 09-15-2015
Pharmaceuticals Subgroup Supported IBB's Stable Performance

Clovis Oncology (CLVS) gained 9.88%, as investors were positive about the company’s presentation at the Morgan Stanley global healthcare conference.

Illumina: A Must-Read Company Overview

An overview of Illumina, a leading biotechnology company, which holds a market capitalization of $27.5 billion.


Please select a profession that best describes you: